SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (596)12/9/2001 3:38:21 PM
From: teevee  Read Replies (1) of 656
 
Richard,
Off topic:
Isotechnika claims that its drug ISAtx247 is a potent immunosuppressant that is well tolerated, but will it have a low rate of opportunistic infections? You stated that universal immunosuppression kills people. Is that comment related to the rate of opportunisitic infections associated with suppressing the immune system? How likely is it that a well tolerated, potent immunosuppressant would have a high rate of opportunistic infections? What are the most likely "infections": bacterial?, viral?, or cell mutations unchecked by the immune system leading to cancer?Thank you for you comments.

regards,
teevee
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News